Mammaglobin-A is a target for breast cancer vaccination

We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Samuel W., Goedegebuure, Peter, Gillanders, William E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801441/
https://www.ncbi.nlm.nih.gov/pubmed/27057470
http://dx.doi.org/10.1080/2162402X.2015.1069940
_version_ 1782422582543253504
author Kim, Samuel W.
Goedegebuure, Peter
Gillanders, William E.
author_facet Kim, Samuel W.
Goedegebuure, Peter
Gillanders, William E.
author_sort Kim, Samuel W.
collection PubMed
description We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadjuvant endocrine therapy, providing a unique opportunity to examine the impact of vaccination in the tumor microenvironment.
format Online
Article
Text
id pubmed-4801441
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48014412016-04-07 Mammaglobin-A is a target for breast cancer vaccination Kim, Samuel W. Goedegebuure, Peter Gillanders, William E. Oncoimmunology Author's View We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadjuvant endocrine therapy, providing a unique opportunity to examine the impact of vaccination in the tumor microenvironment. Taylor & Francis 2016-02-26 /pmc/articles/PMC4801441/ /pubmed/27057470 http://dx.doi.org/10.1080/2162402X.2015.1069940 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author (s) have been asserted.
spellingShingle Author's View
Kim, Samuel W.
Goedegebuure, Peter
Gillanders, William E.
Mammaglobin-A is a target for breast cancer vaccination
title Mammaglobin-A is a target for breast cancer vaccination
title_full Mammaglobin-A is a target for breast cancer vaccination
title_fullStr Mammaglobin-A is a target for breast cancer vaccination
title_full_unstemmed Mammaglobin-A is a target for breast cancer vaccination
title_short Mammaglobin-A is a target for breast cancer vaccination
title_sort mammaglobin-a is a target for breast cancer vaccination
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801441/
https://www.ncbi.nlm.nih.gov/pubmed/27057470
http://dx.doi.org/10.1080/2162402X.2015.1069940
work_keys_str_mv AT kimsamuelw mammaglobinaisatargetforbreastcancervaccination
AT goedegebuurepeter mammaglobinaisatargetforbreastcancervaccination
AT gillanderswilliame mammaglobinaisatargetforbreastcancervaccination

Ejemplares similares